A Study of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis

Diseases and Conditions Researched

Idiopathic Pulmonary Fibrosis

What is the purpose of this trial?

This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of lebrikizumab in patients with idiopathic pulmonary fibrosis. Patients will be randomized to receive either lebrikizumab or placebo subcutaneously every 4 weeks.

Participation Guidelines

Age: 40 Years and older
Gender: Both

Click here for detailed participation information for this trial.

Sponsor: Hoffman-La Roche
Last Updated:
Study HIC#: 1308012528